Company Claims AI-Designed Antibody Clears Allergy Trigger From Immune Cells

Divergence Labs has posted a preprint, an unreviewed research paper dated 29 October 2026, describing an antibody designed with the AI model Claude. The company says its antibody removes allergy-triggering IgE molecules already attached to immune cells. Xolair, an approved allergy drug, instead blocks IgE still circulating in the blood. The paper, the company's own account, targets food allergy.